Dordaviprone clinical trials
Also written ONC201 and TIC10.
How each study uses dordaviprone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dordaviprone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Aug 2025 · MODEYSO · NDA 219876 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 19
Chimerix (5) · University of Nebraska (2) · National Cancer Institute (NCI) (2) · Fox Chase Cancer Center (2) · Rutgers, The State University of New Jersey (2) · Jazz Pharmaceuticals (2) · M.D. Anderson Cancer Center (2) · Peter Anderson (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test dordaviprone.
- May 2027ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerPhase 2 · Ira Winer
Studies
Open first, then newest update. How each study uses dordaviprone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT05476939Written as ONC201How we know
- Testing for Safety and Colorectal Cancer Preventive Effects of ONC201RecruitingPhase 1National Cancer Institute (NCI)NCT05630794Written as Dordaviprone HydrochlorideHow we know
- Combination Therapy for the Treatment of Diffuse Midline GliomasRecruitingPhase 2University of California, San FranciscoNCT05009992Written as ONC201How we know
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerRecruitingPhase 2Ira WinerNCT04055649Written as Akt/ERK Inhibitor ONC201How we know
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)RecruitingPhase 3Jazz PharmaceuticalsNCT05580562Written as Dordaviprone (ONC201)How we know
- ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT05542407Written as ONC201How we know
- Single Agent ONC201 in Recurrent or Metastatic Endometrial CancerTerminatedPhase 2Fox Chase Cancer CenterNCT03099499Written as ONC201How we know
- ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02392572Written as Akt/ERK Inhibitor ONC201How we know
- ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell TransplantCompletedPhase 1University of NebraskaNCT03932643Written as ONC-201How we know
- A Study of ONC201 for Refractory MeningiomaWithdrawnPhase 2University of NebraskaNCT06012929Written as ONC201How we know
- ONC201 in Adults With Recurrent H3 K27M-mutant GliomaTerminatedPhase 2Jazz PharmaceuticalsNCT03295396Written as Dordaviprone (ONC201)How we know
- ONC201 in Pediatric H3 K27M GliomasTerminatedPhase 1ChimerixNCT03416530Written as Dordaviprone (ONC201)How we know
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerTerminatedPhase 2ChimerixNCT03485729Written as Dordaviprone (ONC201)How we know
- Oral ONC201 in Adult Recurrent GlioblastomaTerminatedPhase 2ChimerixNCT02525692Written as Dordaviprone (ONC201)How we know
- Phase 2 Study of ONC201 in Neuroendocrine TumorsCompletedPhase 2Peter AndersonNCT03034200Written as ONC201How we know
- Oral ONC201 in Relapsed/Refractory Multiple MyelomaTerminatedPhase 1/2ChimerixNCT02863991Written as ONC201How we know
- A Phase II, Open Label Study of ONC201 in Adults With EGFR-low GlioblastomaWithdrawnPhase 2Masonic Cancer Center, University of MinnesotaNCT04629209Written as ONC201How we know
- ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompletedPhase 2National Cancer Institute (NCI)NCT03394027Written as ONC201How we know
- Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02420795Written as Akt/ERK Inhibitor ONC201How we know
- ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast CancerTerminatedPhase 2University of Wisconsin, MadisonNCT03733119Written as Akt/ERK Inhibitor ONC201How we know
Codes
What other systems call dordaviprone · ClinicalTrials.gg INT006410
- MeSH (NLM) C585684dordaviproneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9U35A31JAIDORDAVIPRONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27895916DordaviproneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113792DordaviproneOne source FDA
- DrugBank DB14844One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585684 | dordaviprone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9U35A31JAI | DORDAVIPRONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27895916 | Dordaviprone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113792 | Dordaviprone | One source FDA |
| DrugBank | DB14844 | — | One source Wikidata |
Also registered as dordaviprone hydrochloride (UNII 53VG71J90J).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.